Monitoring chimeric antigen redirected (CAR) T-cells post-infusion in clinical trials is a specialized application of flow cytometry. Unlike the CAR T-cell monitoring for individual patients conducted in clinical laboratories, the data generated during a clinical trial will be used not only to monitor the therapeutic response of a single patient, but determine the success of the therapy itself, or even of an entire class of therapeutic compounds. The data, typically acquired at multiple testing laboratories, will be compiled into a single database. The data may also be used for mathematical modeling of cellular kinetics or to identify predictive biomarkers. With the expanded context of use, a robust, standardized assay is mandatory in order to generate a valuable and reliable data set. Hence, the requirements for assay validation, traceable calibration, technology transfer, cross-instrument standardization and regulatory compliance are high.
26 February 2026 in Cytometry Part B: Clinical Cytometry
BCPAP, SW1736, C643, Cal62 control (C), dasatinib-resistant (DR), and dasatinib-resistant cells maintained in 2μM dasatinib in response to indicated concentrations of selumetinib (μM) for 72 hours. Growth was measured by Sulforhodamine B.
A.) IC50 values were calculated using the PRISM software and non-variable slope analysis. Fold increase in sensitivity was calculated based on changes IC50 values in the DasRes + 2μM dasatinib in relation to the DasRes cell line IC50 values.